Assessment of Ventilation-Perfusion Abnormalities in Patients With Stable Smoking-Related Airways Disease

This study is currently recruiting participants.

Verified by Imperial College London, September 2005

Sponsors and Collaborators:	Imperial College London GlaxoSmithKline
Information provided by:	Imperial College London
ClinicalTrials.gov Identifier:	NCT00180843

Purpose

Subjects undergo history, examination, lung function assessment after informed consent has been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is normal they will undergo a second and final scan four weeks later. If abnormal they will undergo two further scans with either nebulized bronchodilator or nebulized saline prior to their second and third scans. Each time they will have repeat lung function tests prior to scanning. We will examine the regional changes in ventilation and perfusion and there relationship to lung function.

Condition	Intervention
Chronic Obstructive Pulmonary Disease	Drug: salbutamol + ipratropium bromide nebules Procedure: ventilation-perfusion scan Procedure: lung function assessment

MedlinePlus related topics: COPD (Chronic Obstructive Pulmonary Disease) Nuclear Scans Smoking

Drug Information available for: Albuterol sulfate Albuterol Levalbuterol hydrochloride Levalbuterol tartrate Ipratropium Ipratropium bromide

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cross-Sectional, Defined Population, Prospective Study
Official Title:	Assessment of Ventilation-Perfusion Abnormalities in Patients With Smoking-Related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy

Further study details as provided by Imperial College London:

Estimated Enrollment:	20
Study Start Date:	September 2005
Estimated Study Completion Date:	November 2008

Eligibility

Ages Eligible for Study:	35 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

FEV1 < 70% predicted at baseline on spirometry
significant smoking history or alpha 1 antitrypsin deficiency
no evidence of current infection or restrictive lung disease

Exclusion Criteria:

history of other significant respiratory disease
significant respiratory infection within 6 weeks
history of significant physical or mental illness rendering them unfit for the study in the opinion of the investigator
taken part in any other research within the past 12 months, or received exposure to ionizing radiation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180843

Contacts

Contact: Philip W Ind, MB Bchir MRCP	02083831000 ext 33269	pind@imperial.ac.uk
Contact: Jason e Burton, MB BS	02083831000 ext 2350	jburton@imperial.ac.uk

Locations

United Kingdom
Imperial College Hammersmith Campus	Recruiting
London, United Kingdom, W12 0HS
Contact: philip w ind, MB B Chir 02083831000 ext 33269 pind@imperial.ac.uk
Principal Investigator: philip w ind, MBBChir MRCP

Sponsors and Collaborators

Imperial College London

GlaxoSmithKline

Investigators

Principal Investigator:

Philip W Ind, MB BChir MRCP

Imperial College Hammersmith

More Information

Study ID Numbers:	04/6741
Study First Received:	September 13, 2005
Last Updated:	September 13, 2005
ClinicalTrials.gov Identifier:	NCT00180843
Health Authority:	United Kingdom: Research Ethics Committee

Study placed in the following topic categories:

Smoking
Lung Diseases, Obstructive
Ipratropium
Respiratory Tract Diseases
Bromides

Lung Diseases
Albuterol
Congenital Abnormalities
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:

Respiratory System Agents
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-Agonists
Adrenergic Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Reproductive Control Agents

Cholinergic Agents
Pharmacologic Actions
Adrenergic Agonists
Tocolytic Agents
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Bronchodilator Agents

ClinicalTrials.gov processed this record on January 16, 2009